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Abstract Syringomycin E is an antifungal cyclic lipodepsino-
napeptide produced by Pseudomonas syringae pv. syringae. To
understand the mechanism of action of syringomycin E, a novel
resistant Saccharomyces cerevisiae strain, BW7, was isolated
and characterized. Lipid analyses revealed that BW7 contained
only the hydrophobic subspecies of sphingolipids that are
normally minor components in wild type strains. This aberrant
sphingolipid composition was the result of lack of K-hydroxyla-
tion of the amide-linked very long chain fatty acids, suggesting a
defective sphingolipid K-hydroxylase encoded by the FAH1 gene.
A yeast strain that lacks the FAH1 gene was resistant to
syringomycin E, and failed to complement BW7. These results
demonstrate that BW7 carries a mutation in the FAH1 gene, and
that the lack of K-hydroxylated very long chain fatty acids in
yeast sphingolipids confers resistance to syringomycin
E. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The plant bacterium Pseudomonas syringae pv. syringae
produces a group of cyclic lipodepsinonapeptides (CLPs)
that include syringomycin E, pseudomycin B, syringotoxin,
and syringostatin [1,2]. The CLPs are considered to be plant
virulence factors, and show a broad range of inhibitory activ-
ities against many fungal species including human pathogens
[3,4]. Biophysical studies revealed that syringomycin E forms
ion channels in arti¢cial lipid bilayers, which may account for
its biological activities [5,6]. To understand the mechanism of
action of syringomycin E in biological membranes, the yeast
Saccharomyces cerevisiae has been used as a model target
organism. Characterization of syringomycin E-resistant yeast
mutants has revealed at least 11 genes that, when mutated,
result in a resistant phenotype [7,8]. These genes are involved
in sterol biosynthesis (SYR1/ERG3 and four uncharacterized
genes) [7,9] or sphingolipid biosynthesis (SYR2, SYR3/ELO2,
ELO3, SYR4/IPT1, CSG1, CSG2) [8,10]. Thus, it appears that
sterols and sphingolipids facilitate the action of syringomycin
E in yeast. In this study, we report the isolation of a novel
syringomycin E-resistant yeast strain with a mutation in the
FAH1 gene. This gene encodes a hydroxylase that introduces
an K-OH in the characteristic very long chain fatty acids
(mostly hexacosanoic acid) of yeast sphingolipids [11,12].
The ¢ndings show that the antifungal action of syringomycin
E requires sphingolipids with K-hydroxylated very long chain
fatty acids (HFA).
2. Materials and methods
2.1. Strains and media
S. cerevisiae strains used in this study were W303C (MATa ura3-52
his3-v200 lys2-801) [10], BW7 (MATa ura3-52 his3-v200 lys2-801
fah1) (this work), BY4742 (MATK his3v1 leu2v0 lys2v0 ura3v0)
[13] (Research Genetics, Huntsville, AL), and BY4742 fah1v
(MATK his3v1 leu2v0 lys2v0 ura3v0 fah1v0) (Research Genetics,
Huntsville, AL), BWBY4742 (a diploid strain made by crossing
BW7 to BY4742), and BWBY fah1v (a diploid strain made by cross-
ing BW7 to BY4742 fah1v). Yeast cells were grown in a medium with
1% yeast extract, 2% peptone, and 2% glucose (YPD medium). Sy-
ringomycin E was puri¢ed from cultures of P. syringae pv. syringae
strain B301D as previously described [14].
2.2. Isolation of syringomycin E-resistant mutants
Mutants resistant to syringomycin E were generated by UV muta-
genesis. W303C cells were plated on YPD medium agar plates and
illuminated with UV (312 nm) for 30 s (10% survival rate). Colonies
were tested for syringomycin E resistance by replica plating on YPD
medium agar containing 0.5 Wg/ml syringomycin E.
2.3. Lipid analyses
Ergosterol levels were measured by the method of Woods [15].
Labeling of yeast cells [8], sphingolipid extraction [16], and TLC
[17] were conducted as described previously.
For very long chain fatty acid analyses, total lipids were extracted
from 20 OD600 units of cells by the method of Hanson and Lester [16].
Fatty acids were liberated from the crude lipid extracts by alkaline
treatment, and were derivatized as described in [18]. Fatty acid phe-
nacyl derivatives were resuspended in 200 Wl of acetonitrile/methanol
(40:60, v/v) by sonication, and 20 Wl of each sample was used for
HPLC analysis. Reversed-phase HPLC was carried out using a Beck-
man System Gold HPLC unit equipped with a Beckman Ultrasphere
XL ODS column (3 Wm particles, 4.6U70 mm). The column was
equilibrated with acetonitrile/methanol (40:60, v/v) at 1 ml/min. Fatty
acid phenacyl derivatives were eluted with 2 ml of acetonitrile/meth-
anol (40:60, v/v), and then with a 15 ml linear gradient to acetonitrile/
methanol (25:75, v/v). UV absorption was monitored at 242 nm.
Hexacosanoic acid (C26) and K-hydroxyhexacosanoic acid (C26-
OH) standards were purchased from Sigma.
3. Results
3.1. Isolation of novel syringomycin E-resistant mutants
Previous analyses of syringomycin E-resistant yeast mu-
tants, generated by nitrosoguanidine mutagenesis, identi¢ed
11 genes that are involved in susceptibility to syringomycin
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E [7^10]. To isolate additional mutants, rigorous UV irradi-
ation mutagenesis was conducted (survival rate of 10%). From
500 colonies screened for resistance to 0.5 Wg/ml syringomycin
E, seven resistant strains were isolated. Among these, two
strains, BW1 and BW7, were more resistant and able to
grow in the presence of 0.75 Wg/ml syringomycin E. Sphingo-
lipid analyses revealed that strain BW1 was likely to be a syr4
mutant (not shown) [8]. Strain BW7, on the other hand, did
not resemble known syringomycin E-resistant strains, and it
was selected for further study.
3.2. Lipid analyses of the new syringomycin E-resistant mutant
To determine whether strain BW7 was defective in sterol
biosynthesis, ergosterol levels in non-saponi¢able lipid ex-
tracts were measured. Strain BW7 contained ergosterol at
levels similar to the wild type strain, indicating that syringo-
mycin E resistance was not due to altered sterol biosynthesis
(data not shown).
Sphingolipid analysis was conducted to determine whether
strain BW7 had a defect in sphingolipid biosynthesis. Thin-
layer chromatography of 32P-labeled sphingolipids revealed
that strain BW7 possessed the three major types of yeast
sphingolipids, inositolphosphorylceramide (IPC), mannosyli-
nositolphosphorylceramide (MIPC), and mannosyldiinositol-
phosphorylceramide [M(IP)2C] (Fig. 1). However, the subspe-
cies pro¢les of each of these sphingolipids were markedly
altered in the mutant. The major wild type forms of IPC,
MIPC, and M(IP)2C were missing in strain BW7, and instead,
more hydrophobic (higher mobility) subspecies, normally mi-
nor, were prominent. This suggests that the mutant lacked a
modi¢cation that renders its sphingolipids more hydrophilic.
Two enzymes are known to introduce hydrophilic modi¢-
cations to the ceramide portion of yeast sphingolipids [19] :
the SYR2 gene product catalyzes C4-hydroxylation of the long
chain base [20], and the FAH1 gene product is required for the
K-hydroxylation of the amide-linked very long chain fatty
acids [12,21]. When strain BW7 was crossed to a strain with
a SYR2 deletion, the resulting diploid strain was sensitive to
syringomycin E, demonstrating that the mutation in strain
BW7 does not reside in the SYR2 gene (data not shown).
Therefore, it was speculated that the mutant lacked the
HFA due to a mutation in the FAH1 gene.
3.3. Defects in sphingolipid K-hydroxylation in strain BW7
The presence of HFA in strain BW7 was analyzed. Total
cellular fatty acids were extracted and converted to UV-ab-
sorbing phenacyl derivatives for HPLC analyses. As expected,
the C26 fatty acids of the wild type strain, W303C, were
mostly hydroxylated (HFA) (Fig. 2) [17]. Strain BW7, how-
ever, contained non-hydroxylated C26 fatty acids (NFA) and
HFA were not detected. Similarly, strain BY4742 (a FAH1
strain) contained mostly HFA, and the same strain with a
FAH1 deletion (BY4742 fah1v) contained only NFA. Strain
BY4742 fah1v showed a similar degree of resistance to syrin-
gomycin E as strain BW7 (Fig. 3). These results strongly
suggest that strain BW7 carries a mutation in the FAH1
gene. This possibility was directly tested by genetic comple-
mentation analyses between strains BW7 and BY4742 fah1v.
A cross between strains BW7 and BY4742 resulted in a dip-
loid (strain BWBY4742) that contained HFA (Fig. 2) and that
displayed sensitivity to syringomycin E (Fig. 3). In contrast, a
cross between strain BW7 and BY4742 fah1v resulted in a
diploid strain (BWBY fah1v) that contained only NFA
Fig. 1. Altered sphingolipid composition of strain BW7. Total lipids
were extracted from [32P]phosphate-labeled cells and deacylated by
mild alkaline treatment. Alkaline-resistant phospholipids were re-
solved by TLC (solvent: CHCl3/methanol/4.2 N NH4OH, 9:7:2,
v/v), and visualized by autoradiography. The major sphingolipid
classes of yeast are indicated. Lane 1, W303C; lane 2, BW7.
Fig. 2. HPLC analyses of very long chain fatty acids of strain BW7
and fah1 mutants. Fatty acids were liberated from cellular lipids by
alkaline treatment. UV-absorbing phenacyl derivatives were ana-
lyzed by reversed-phase HPLC. The peaks eluting between 30 s and
4 min include shorter chain fatty acid derivatives and excess deriva-
tization reagents.
Fig. 3. Syringomycin E-resistant phenotype of fah1 mutants. Each
strain (V1U107 cells) was suspended in 100 Wl of YPD medium,
replica plated onto YPD agar plates with or without 0.75 Wg/ml sy-
ringomycin E, and the plates incubated at 29‡C for 48 h. 1, W303C;
2, BW7; 3, BY4742; 4, BY4742 fah1v ; 5, BWBY4742; 6, BWBY
fah1v.
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(Fig. 2), and was resistant to syringomycin E (Fig. 3). These
results demonstrate that strain BW7 carries a mutation in the
FAH1 gene, and that the lack of HFA results in resistance to
syringomycin E.
With the three fah1 strains the growth was slightly stimu-
lated by syringomycin E (Fig. 3). Although the mechanism
is not known, similar phenomena have been observed with
syr1/erg3 strains [22] and other syringomycin E-resistant
strains (unpublished).
3.4. Lack of HFA and resistance to other antifungal agents
Yeast cells exhibit cross-resistance against several antifungal
agents when pleiotropic drug resistance (PDR) genes are in-
duced [23]. To determine whether the lack of HFA induces the
PDR genes, susceptibility to other antifungal agents was
studied. The fah1 strains showed susceptibilities to amphoter-
icin B, calco£uor, cycloheximide, ketoconazole, and nystatin,
indicating that a PDR gene-related mechanism is not involved
(data not shown). Interestingly, strain BW7 was more resis-
tant to another cyclic lipodepsinonapeptide, pseudomycin B
(minimal inhibitory concentration = 2.5 Wg/ml), compared to
the parental strain (minimal inhibitory concentration = 0.32
Wg/ml). Consistent with these observations, characterization
of pseudomycin B-resistant yeast mutants identi¢ed strains
with fah1 mutations (unpublished).
4. Discussion
In this study, we demonstrated that HFA in yeast sphingo-
lipids promote sensitivity to syringomycin E. The e¡ect ap-
pears to be speci¢c for the cyclic lipodepsinonapeptides, since
resistance to both syringomycin E and pseudomycin B, but
not to other antifungal agents, was evident in fah1 mutants. It
is not yet known how HFA facilitates syringomycin E action
at the plasma membrane. The HFA K-OH participates in
intra- and intermolecular hydrogen bonding and in£uences
interchain packing in membranes [24,25]. In fah1 mutants,
the lack of HFA would signi¢cantly decrease hydrogen bond-
ing capacity and lipid^lipid interactions. One possibility is
that the K-OH allows hydrogen bonding of syringomycin E
directly to sphingolipids to facilitate ion channel formation in
the membrane. Alternatively, K-hydroxylation may enhance
formation of sterol/sphingolipid-rich membrane domains (lip-
id rafts), which may serve as sites for syringomycin E binding
and channel formation.
S. cerevisiae contains lipid rafts that are highly enriched
with ergosterol and sphingolipids, and depletion of these lip-
ids compromises raft integrity [26]. In addition to HFA, the
antifungal action of syringomycin E also requires ergosterol
[7,9] and sphingolipid modi¢cations that increase lipid^lipid
interactions [8,10,20], suggesting further the involvement of
lipid rafts. Association of syringomycin E to lipid rafts would
increase local concentrations to facilitate formation of the
oligomeric syringomycin E channels. The lack of HFA and
the other sphingolipid modi¢cations may compromise raft
integrity, causing raft-associated molecules to di¡use ^ an
e¡ect that would decrease the ability of syringomycin E to
form ion channels. Consistent with this idea, the growth of
fah1 mutants is only inhibited by syringomycin E at much
higher concentrations (above 2 Wg/ml), which may re£ect
non-raft-mediated ion channel formation. Therefore, it is of
interest to examine the integrity of lipid rafts in fah1 mutants,
and to correlate it with the e⁄ciency of ion channel formation
by syringomycin E.
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